Intas is a leading pharmaceutical company based in India with a track record of consistently strong growth in both the domestic and export markets.
Specialized in generic drugs for chronic diseases, Intas is a leader in the Indian chronic pharma market, which grew at a significantly higher rate than the acute pharma market in the years prior to CIPEF VI’s investment. Growth in the chronic segment is driven by a combination of a steady rise in disease prevalence, higher spending power to undertake treatments, and improved accessibility to drugs. India is currently the second fastest growing pharma market in the world.
In addition to a favorable market position in India, Intas has a strong international presence with sales in over 70 countries.
